ResMed (RMD) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $228.35 --0%
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $0.65, in-line with the analyst estimate of $0.65. Revenue for the quarter came in at $422.5 million versus the consensus estimate of $425.76 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Bernstein SocGen Group Reiterates Outperform Rating on Robinhood Markets (HOOD)
- GE Aerospace to acquire Consolidated Precision in $11.75b deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
